Tetrahydro-Pyrido-Pyrimidine Derivatives

Abstract

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R 1 , R 2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

1 - 20 . (canceled) 
     
     
         21 . A salt form of 1-((S)-3-[6-(6-Methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl)-propan-1-one, wherein the salt form comprises an anion selected from phosphate, chloride or hippurate. 
     
     
         22 . The salt form according to  claim 21 , wherein the anion is phosphate. 
     
     
         23 . The salt according to  claim 22  in anhydrous form. 
     
     
         24 . The salt form according to  claim 23 , characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta: 11.6, 16.6, 20.7 and 23.3. 
     
     
         25 . The salt form according to  claim 23 , characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta: 9.8, 11.6, 16.6, 19.5, 20.7 and 23.3. 
     
     
         26 . The salt form according to  claim 21 , wherein the anion is chloride. 
     
     
         27 . The salt according to  claim 26  in anhydrous form. 
     
     
         28 . The salt form according to  claim 27 , characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta: 5.6, 11.3 and 23.1. 
     
     
         29 . The salt form according to  claim 27 , characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta: 5.6, 11.3, 14.7, 19.4 and 23.1. 
     
     
         30 . The salt form according to  claim 21 , wherein the anion is hippurate. 
     
     
         31 . The salt according to  claim 30 , in anhydrous form. 
     
     
         32 . The salt form according to  claim 31 , characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta: 5.2, 7.5, 23.2 and 24.2. 
     
     
         33 . The salt form according to  claim 31 , characterized by an X-Ray powder diffraction pattern comprising the following peaks given at degrees 2-Theta: 5.2, 7.5, 10.3, 10.9, 23.2 and 24.2. 
     
     
         34 . A pharmaceutical composition comprising a therapeutically effective amount of a salt form according to  claim 21 , and one or more pharmaceutically acceptable carriers. 
     
     
         35 . A pharmaceutical combination comprising a therapeutically effective amount of a salt form according to  claim 21 , and one or more therapeutically active agents. 
     
     
         36 . A method of modulating the activity of PI3Kδ isoform in a subject, the method comprising the step of administering to a subject a therapeutically effective amount of a salt form according to  claim 21 . 
     
     
         37 . The method of  claim 36 , wherein the anion of the salt form is phosphate. 
     
     
         38 . The method of  claim 36 , wherein the anion of the salt form is chloride. 
     
     
         39 . The method of  claim 36 , wherein the anion of the salt form is hippurate.